President Donald Trump escalated his campaign to lower U.S. drug prices by demanding 17 major pharmaceutical companies provide ‘most favored nation’ pricing for Medicaid and Medicare drugs within 60 days. The White House called for prices to align with the lowest levels charged by OECD countries with substantial GDP and requested the expansion of direct-to-consumer sales and repatriation of foreign revenues. Industry leaders, including AstraZeneca and PhRMA, have expressed concerns over the proposal's impact on innovation and pricing dynamics. This directive follows earlier executive orders targeting drug pricing disparities and has shaken investor confidence in pharma stocks.